Successful use of recombinant activated coagulation factor VII in a patient with massive hemoptysis from a penetrating thoracic injury.
Acute massive hemoptysis is a rare complication of pulmonary injury and contusion, and it is particularly difficult to manage in the nontertiary care setting. Recombinant activated coagulation factor VII (rFVIIa) is a prothrombotic drug that is increasingly being used to treat coagulopathy in massively exsanguinating trauma patients. We report a case in which recombinant activated coagulation factor VII successfully controlled massive hemoptysis and improved ventilation from a severe pulmonary contusion in a noncoagulopathic patient who suffered a penetrating thoracic injury in a military setting in Afghanistan.
Tien
Homer C N
HC
The Trauma Program and the Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. homer.tien@sunnybrook.ca
Gough
Michael R C
MR
Farrell
Robert
R
Macdonald
John
J
D000328:Adult; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D015942:Factor VIIa / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006469:Hemoptysis / Q000209:etiology / Q000628:therapy*; D006490:Hemostatics / Q000008:administration & dosage; D006801:Humans; D055370:Lung Injury; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D018570:Risk Assessment; D012720:Severity of Illness Index; D013898:Thoracic Injuries / Q000150:complications* / Q000175:diagnosis; D013908:Thoracotomy / Q000379:methods; D016896:Treatment Outcome; D014948:Wounds, Gunshot / Q000150:complications* / Q000175:diagnosis
D006490:Hemostatics; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa